Tirzepatide vs Semaglutide

Tirzepatide and semaglutide are both long-acting incretin-based peptides delivered by once-weekly subcutaneous injection. Semaglutide, approved first, established the modern benchmark for GLP-1 receptor agonist weight loss (~15% of baseline body weight on 2.4 mg). Tirzepatide raised that ceiling by adding GIP receptor agonism, producing mean weight reductions of 20–22% on 15 mg in the SURMOUNT programme and outperforming semaglutide head-to-head in SURPASS-2. Semaglutide retains a unique advantage: a completed cardiovascular outcomes trial (SELECT, 2023) in obesity without diabetes. The clinical choice rests on therapeutic goal, prior tolerance, comorbidity, and access.

Semaglutide is a 31-amino-acid analogue of native GLP-1 with two strategic substitutions (Aib8, Arg34) and a C-18 fatty di-acid linker that drives albumin binding. The result is enzymatic resistance to DPP-4 and a half-life of approximately seven days. Agonism of GLP-1 receptors in pancreatic β-cells amplifies glucose-dependent insulin release; central GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem reduce hunger, slow gastric emptying, and dampen food-reward signalling.

Tirzepatide is a 39-amino-acid synthetic peptide engineered from the native GIP scaffold and activates BOTH the GIP and GLP-1 receptors with balanced potency. Adding GIP agonism appears to enhance insulin sensitivity in adipose tissue, modulate energy expenditure, and counteract some of the nausea-related downsides of pure GLP-1 activation. A C-20 fatty acid extends the half-life to roughly five days. Dual agonism — not higher GLP-1 potency alone — is the mechanistic basis for the larger weight-loss signal.

SURMOUNT-1 (NEJM 2022) randomised 2 539 adults without diabetes to placebo or weekly tirzepatide 5/10/15 mg over 72 weeks. Mean weight reductions reached 15.0%, 19.5% and 20.9% — vs 3.1% on placebo. More than half of the 15 mg arm lost ≥20% of baseline body weight. STEP-1 (NEJM 2021) randomised 1 961 adults to weekly semaglutide 2.4 mg or placebo over 68 weeks. Mean weight loss was 14.9% vs 2.4%.

The single head-to-head trial, SURPASS-2 (NEJM 2021), enrolled 1 879 adults with type 2 diabetes and compared tirzepatide 5/10/15 mg to semaglutide 1 mg over 40 weeks. All tirzepatide doses produced superior HbA1c and weight reductions; the 15 mg arm achieved a mean −11.2 kg weight change vs −5.7 kg with semaglutide. Note this study used the 1 mg diabetes dose of semaglutide rather than the 2.4 mg obesity dose, so the magnitude of the gap in pure obesity populations is somewhat smaller than SURPASS-2 implies.

In type 2 diabetes, tirzepatide 15 mg reduces HbA1c by 2.0–2.4 percentage points across the SURPASS programme; semaglutide 1 mg achieves 1.5–1.8 points and 2.0 mg approximately 2.0 points (SUSTAIN-FORTE). Both produce robust fasting and post-prandial glucose improvements and are weight-loss neutral or favourable to nearly every other oral antihyperglycaemic.

Semaglutide is currently the only peptide in this class with completed cardiovascular outcomes data in obesity without diabetes. SELECT (NEJM 2023) randomised 17 604 adults with prior CV disease and BMI ≥27 to semaglutide 2.4 mg or placebo. Over a mean 40 months, MACE (CV death, non-fatal MI, non-fatal stroke) was reduced by 20% (HR 0.80, 95% CI 0.72–0.90). In type 2 diabetes, SUSTAIN-6 and PIONEER 6 previously showed CV benefit. Tirzepatide cardiovascular outcomes trials (SURPASS-CVOT vs dulaglutide, and SURMOUNT-MMO in obesity) are ongoing, with read-outs expected 2025–2027.

Both peptides require slow titration to mitigate GI effects. Semaglutide for obesity: 0.25 mg weekly ×4 → 0.5 → 1.0 → 1.7 → 2.4 mg maintenance (≈20 weeks to target). Tirzepatide: 2.5 mg weekly ×4 → 5 → 7.5 → 10 → 12.5 → 15 mg maintenance, escalating by 2.5 mg every four weeks if tolerated.

Inject subcutaneously in abdomen, thigh, or upper arm and rotate sites. When switching FROM semaglutide TO tirzepatide, most clinicians wash out one week and restart titration at 2.5 mg regardless of the prior semaglutide dose, because there is no validated dose-equivalence between the two molecules. Holding the current dose tier longer is preferable to pushing through intolerable nausea.

Both share the GLP-1 class adverse-event profile: nausea, vomiting, diarrhea, constipation, reflux, and rare pancreatitis or gallbladder events. In SURPASS-2, GI adverse event rates were broadly similar between the two molecules. Tirzepatide users sometimes report somewhat more early-titration nausea but better long-term tolerability, possibly because GIP agonism dampens the central nausea signal once at steady state. Discontinuation rates for adverse events were ~5–7% with tirzepatide and ~4–6% with semaglutide.

• Both carry a US black-box warning for medullary thyroid C-cell tumours observed in rodent models; contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2.
• Rare acute pancreatitis — discontinue if severe persistent abdominal pain develops.
• Slowed gastric emptying may delay absorption of oral medications, including hormonal contraceptives.
• Not for use in pregnancy or breastfeeding. Discontinue at least 2 months before planned conception.
• Caution in severe gastroparesis, prior bariatric surgery, or active gallbladder disease.

• SURMOUNT-1 — Tirzepatide once weekly for obesity

  New England Journal of Medicine · 2022

  2 539 adults; mean weight loss 15.0%, 19.5%, 20.9% on 5, 10, 15 mg vs 3.1% placebo at 72 weeks.

• STEP-1 — Semaglutide 2.4 mg in overweight/obesity

  New England Journal of Medicine · 2021

  1 961 adults; mean weight loss 14.9% vs 2.4% placebo at 68 weeks.

• SURPASS-2 — Tirzepatide vs semaglutide 1 mg in T2D

  New England Journal of Medicine · 2021

  All tirzepatide doses produced superior HbA1c and weight reduction at 40 weeks.

• SELECT — Semaglutide and CV outcomes in obesity without diabetes

  New England Journal of Medicine · 2023

  17 604 patients; 20% relative MACE reduction over mean 40 months.